PMID- 33582590
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20240226
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 94
DP  - 2021 May
TI  - Inhibitory effects of cyanidin-3-O-glucoside in black soybean hull extract on 
      RBL-2H3 cells degranulation and passive cutaneous anaphylaxis reaction in mice.
PG  - 107394
LID - S1567-5769(21)00030-8 [pii]
LID - 10.1016/j.intimp.2021.107394 [doi]
AB  - Black soybean hull extract (BSHE) exhibits a variety of biological activities. 
      However, little is known about the effects of BSHE on immunoglobulin E 
      (IgE)-mediated type I allergic reactions. The anti-allergic effect of BSHE was 
      assessed with the degranulation assay using rat basophilic leukemia RBL-2H3 cells 
      and the passive cutaneous anaphylaxis (PCA) reaction in mice. An active compound 
      in BSHE was identified by ultra-performance liquid chromatography coupled to 
      diode array detection and electrospray ionization tandem mass spectrometry 
      analysis. BSHE inhibited the release of beta-hexosaminidase and histamine in RBL-2H3 
      cells, and cyanidin-3-O-glucoside (C3G) was identified as one of its active 
      compounds. Oral administering of 200 mumol/kg of C3G to IgE-sensitized mice prior 
      to antigen injection suppressed the PCA reaction, as compared with control 
      (p < 0.01). Intravenous administration of BSHE (C3G content, 5.4%) more strongly 
      inhibited PCA responses at lower doses (100 mg/kg, p < 0.01) than oral 
      administration (1,000 mg/kg, p = 0.059). Intravenous C3G also suppressed PCA 
      response at a low dose (40 mg/kg, p < 0.05), showing the same trend as BSHE. This 
      information can be useful to design appropriate formulations of anthocyanin-based 
      drug products to suppress allergic reactions. This study provides evidence for 
      the potential use of BSHE and C3G for the prevention or the treatment of type I 
      allergies.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Hiemori-Kondo, Miki
AU  - Hiemori-Kondo M
AD  - Department of Food Nutritional Science, Tokushima Bunri University, 180 
      Nishihama, Yamashiro, Tokushima 770-8514, Japan; Department of Nutritional 
      Science, Okayama Prefectural University, 111 Kuboki, Soja, Okayama 719-1197, 
      Japan. Electronic address: m-kondo@tks.bunri-u.ac.jp.
FAU - Morikawa, Etsuko
AU  - Morikawa E
AD  - Department of Nutritional Science, Okayama Prefectural University, 111 Kuboki, 
      Soja, Okayama 719-1197, Japan.
FAU - Fujikura, Michiko
AU  - Fujikura M
AD  - Department of Nutritional Science, Okayama Prefectural University, 111 Kuboki, 
      Soja, Okayama 719-1197, Japan.
FAU - Nagayasu, Ayuko
AU  - Nagayasu A
AD  - Department of Nutritional Science, Okayama Prefectural University, 111 Kuboki, 
      Soja, Okayama 719-1197, Japan.
FAU - Maekawa, Yuuki
AU  - Maekawa Y
AD  - Department of Food Nutritional Science, Tokushima Bunri University, 180 
      Nishihama, Yamashiro, Tokushima 770-8514, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210211
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anthocyanins)
RN  - 0 (Plant Extracts)
RN  - 0 (cyanidin-3-O-beta-glucopyranoside)
RN  - EC 3.2.1.- (Hexosaminidases)
SB  - IM
MH  - Animals
MH  - Anthocyanins/*pharmacology/*therapeutic use
MH  - Cell Degranulation/*drug effects
MH  - Cell Line
MH  - Hexosaminidases/metabolism
MH  - Histamine Release/drug effects
MH  - Male
MH  - Mice, Inbred ICR
MH  - Passive Cutaneous Anaphylaxis/*drug effects
MH  - Plant Extracts
MH  - Rats
MH  - Glycine max
MH  - Mice
OTO - NOTNLM
OT  - Anti-allergy
OT  - Black soybean hull extract
OT  - Cyanidin-3-O-glucoside
OT  - Passive cutaneous anaphylaxis reaction
OT  - RBL-2H3 cells
EDAT- 2021/02/15 06:00
MHDA- 2021/06/23 06:00
CRDT- 2021/02/14 20:34
PHST- 2020/10/04 00:00 [received]
PHST- 2020/12/28 00:00 [revised]
PHST- 2021/01/11 00:00 [accepted]
PHST- 2021/02/15 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
PHST- 2021/02/14 20:34 [entrez]
AID - S1567-5769(21)00030-8 [pii]
AID - 10.1016/j.intimp.2021.107394 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2021 May;94:107394. doi: 10.1016/j.intimp.2021.107394. Epub 
      2021 Feb 11.